Skip to main content Skip to search Skip to main navigation
News: EMA

EMA: New Q&A on nitrosamine impurities for marketing authorisation holders

Shortly after the publication of the EMA's final assessment report on nitrosamine impurities in medicinal products (we reported), a 15-page Q&A for marketing authorisation holders and applicants was published on 6 August 2020.

It replaces the document 'Information on nitrosamines for marketing authorisation holders' EMA/428592/2019 published in September 2019, which was withdrawn.   

 

The 18 questions and answers on the topic of "risk assessment" deal with the expectations that will be placed on marketing authorisation holders and applicants in the future. They are intended to

  • design their manufacturing processes and controls to prevent if possible or mitigate as much as possible the presence of N-nitrosamines in their API and FP(s); 
  • assess the risk of presence nitrosamine impurities in their API(s) and FP(s) and introduce any resultant changes to the dossier as needed (e.g. changes to their manufacturing processes); 
  • ensure that active substances and excipients used in their FPs are manufactured in compliance with good manufacturing practices in line with Article 46(f) of Directive 2001/83/EC. 

 

What's new?

While in September 2019 the "Call for Review" concentrated on impurities in chemically synthesized active pharmaceutical ingredients, biological APIs must now also be reviewed. In particular these are

  • biologicals containing chemically synthesised fragments, where risk factors similar to chemically synthesised active substances are present;
  • biologicals using processes where nitrosating reagents are deliberately added;  
  • biologicals packaged in certain primary packaging material, such as blister packs containing nitrocellulose. 

The "Call for Review" is divided into three steps.:

  • Step 1: Risk evaluation   
  • Step 2: If a risk exists, confirmatory tests must be performed and the results must be reported immediately.  
  • Step 3: If the presence of nitrosamines is confirmed, variations to reduce the risk should be submitted.  

 

Important deadlines for marketing authorisation holders to submit the results from step 1: 

  • for products containing chemically synthesised APIs: until 31 March 2021  
  • for products containing biological APIs: until 1 July 2021 

 

The Q&A also provides answers to questions on the following points:  

  • Currently known causes for the presence of nitrosamines 
  • Procedure after completion of steps 1 and 2 if new information becomes available   
  • Prioritization of certain factors in the risk assessment 
  • Performance of the risk assessment 
  • Conduction of the confirmatory tests 
  • Requirements for the analytical methods 
  • Limits for nitrosamines 
  • What-To-Do after detection of nitrosamine contamination 
  • Mitigation measures 
  • Changes required for marketing authorisations 
  • Procedure for new and existing marketing authorisation applications 
  • Information on the time of inclusion of a test for nitrosamines in the authorisation dossier 
  • Responsibilities of marketing authorisation holders for active substances with Certificates of Suitability (CEPs) and Active Substance Master Files (ASMFs)

Sources:

EMA: Nitrosamine Website

EMA: Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may Also be Interested in the Following Articles

News: ICH

ICH: Adoption of the ICH Q1 Stability Guideline

The Assembly of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) met on 17-18 November 2026 in Prague, Czechia for its biannual meeting. ICH announced, among other things, adoption of ICH Q1: Stability Testing of Drug Substances and Drug Products as a final harmonised guideline.
Read more
FDA Expands Sampling and Testing of Marketed Medicines

FDA Expands Sampling and Testing of Marketed Medicines

Through its Enhanced Approach for Sampling and Testing (EAST) program, the US Food and Drug Administration combines rapid analytical techniques with established testing methods. The agency aims to test more medicines from US and overseas manufacturers, detect potential quality issues earlier, and use the findings to inform risk-based inspection planning.
Read more
FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

At the PDA/FDA Joint Regulatory Conference 2026, FDA made it clear that modern equipment alone does not ensure sterility assurance. The article examines GMP deficiencies identified during FDA inspections and the role of facility design in aseptic manufacturing.

Read more
Question of the Week | GMP-Verlag

How is Qualification Carried out in Accordance With the V-model Described in GAMP® 5?

Here's the answer:
Read more
News: Medical Devices

EMA: Harmonisation of Combination-Product Quality Assessment

EMA’s Combination Products Operational Group (COMBO) is working to improve alignment between notified body opinions (NBOps) and pharmaceutical quality assessment, according to its report on the meeting held on 8 October 2026.
Read more
PIC/S: Revision of the Framework for International Cooperation

PIC/S: Revision of the Framework for International Cooperation

PIC/S has revised the framework governing its international cooperation. The updated Pharmaceutical Inspection Co-operation Scheme, PIC/S 1/95 (Rev. 7), was adopted in Istanbul on 2 November 2026 and entered into force on the same day.
Read more
Previous
Next